总时间（秒）：814.20
问答时间（秒）：812.42

{
    "functional_evidence_assessment": [
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the wild-type protein
            "alt": "N/A",
            "position": "N/A"
          },
          "variant_string_id": "LRRK2 N/AN/AN"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The paper uses pathogenic LRRK2 mutants as controls
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 2 // The paper uses at least 2 pathogenic LRRK2 mutants as controls
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 N/AR1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 N/AG2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 N/AY1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 N/AR1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 N/AG2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 NY1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 N/AR1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 NG2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 NR1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 NI2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 NG2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 NR1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 NG2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 NY1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 G2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 G2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 Y1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 Y1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 G2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 G2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 Y1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 G2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2385R mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2385R mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2385R is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the Y1699C pathogenic mutant of LRRK2
            "alt": "Y1699C",
            "position": "1699"
          },
          "variant_string_id": "LRRK2 Y1699C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the Y1699C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The Y1699C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and Y1699C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the I2020T pathogenic mutant of LRRK2
            "alt": "I2020T",
            "position": "2020"
          },
          "variant_string_id": "LRRK2 I2020T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the I2020T mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The I2020T mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and I2020T is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2019S pathogenic mutant of LRRK2
            "alt": "G2019S",
            "position": "2019"
          },
          "variant_string_id": "LRRK2 G2019S"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the G2019S mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The G2019S mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and G2019S is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the R1441C pathogenic mutant of LRRK2
            "alt": "R1441C",
            "position": "1441"
          },
          "variant_string_id": "LRRK2 R1441C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mutants and the R1441C mutant itself as positive controls
                  },
                  {
                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                    "answer": false // No explicit statement about replication is found in the paper
                  }
                ],
                "internal_judgment": true // Basic controls are present, but no information on replication is provided
              },
              {
                "sub_step_name": "Sub-step 3b: Accepted/Validated Assay",
                "internal_questions": [
                  {
                    "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?",
                    "answer": false // No information is provided that suggests the assay is a standard technique or previously validated
                ],
                "internal_judgment": false // The assay is not broadly accepted historically, not previously validated, and not provided as a commercial kit with defined performance metrics
              },
              {
                "sub_step_name": "Sub-step 3c: Variant Controls",
                "internal_questions": [
                  {
                    "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LS (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?",
                    "answer": true // The R1441C mutant is used as a positive control and compared to the wild-type protein
                  }
                ],
                "internal_judgment": true // Variant controls are used
              },
              {
                "sub_step_name": "Sub-step 4a: Statistical Analyses",
                "internal_questions": [
                  {
                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays)",
                    "answer": false // No statistical analysis is provided for this variant
                  }
                ],
                "internal_judgment": false // No OddsPath calculation is possible due to the lack of statistical analysis
              },
              {
                "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                "internal_questions": [
                  {
                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                    "answer": 3 // The paper uses at least 2 pathogenic LRRK2 mutants as controls, and R1441C is a known pathogenic mutant, so at least 3 pathogenic variants are used in total across the study
                  }
                ],
                "internal_judgment": true // At least 11 variant controls are used in total across the study, so the functional evidence strength is Max PS3_moderate
              }
            ]
          }
        ],
        "functional_evidence_strength": "Max PS3_moderate"
      },
      {
        "variant_id": {
          "Gene": "LRRK2",
          "Protein_Change": {
            "ref": "N/A", // No reference amino acid change is mentioned, but this is the G2385R pathogenic mutant of LRRK2
            "alt": "G2385R",
            "position": "2385"
          },
          "variant_string_id": "LRRK2 G2385R"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
          {
            "step_name": "Step 1: Define the disease mechanism",
            "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the ﬁrst time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
            "extracted_paper_info": "The paper uses an in vitro kinase assay, which effectively models or reflects the disease pathogenesis by demonstrating a direct interaction between LRRK2 and Akt1.",
            "internal_judgment": true
          },
          {
            "step_name": "Step 3: Evaluate validity of specific instances of assays",
            "sub_steps": [
              {
                "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                "internal_questions": [
                  {
                    "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                    "answer": true // The paper mentions using a wild-type protein as well as pathogenic LRRK2 mut